重大资产重组！大牛股，今日复牌！

Core Viewpoint - Multiple A-shares are set to resume trading, with significant asset restructuring announcements from Dongtu Technology and Weigao Blood Purification [1][6] Group 1: Dongtu Technology - Dongtu Technology plans to acquire 100% of Gaoweike through a combination of issuing shares and cash payments, with the stock resuming trading on November 3 [2] - The acquisition is expected to meet the criteria for a major asset restructuring, with the share price set at 18.56 yuan per share, which is 80% of the average trading price over the last 120 trading days [2] - Gaoweike, established in 2001, specializes in industrial automation and control systems, serving various sectors including new energy batteries and consumer electronics [3] - The acquisition aims to enhance Dongtu Technology's capabilities in providing comprehensive solutions and improve its competitiveness in the market [4] - In the first three quarters of 2025, Dongtu Technology reported a revenue of 500 million yuan, a year-on-year decrease of 11.72%, primarily due to a strategic shift in business structure [4] - New business segments, including smart controllers and industrial operating systems, showed significant growth, with order amounts increasing by 87.55% and 13.63% respectively [4] - Dongtu Technology is also strategically investing in the embodied robotics sector, indicating a broader focus on technological advancements [5] Group 2: Weigao Blood Purification - Weigao Blood Purification intends to acquire 100% of Weigao Puri through a share issuance, with the stock also resuming trading on November 3 [6] - The acquisition is anticipated to constitute a major asset restructuring, with the valuation and transaction price yet to be determined [6] - Weigao Puri, founded in 2005, is a leading manufacturer of pre-filled syringes, holding over 50% market share in China and ranking among the top five globally [6][7] - Post-acquisition, Weigao Blood Purification will diversify its business to include the development and production of medical packaging products, enhancing its resilience and growth potential [7] - For the first three quarters of this year, Weigao Blood Purification reported total revenue of 2.736 billion yuan, a year-on-year increase of 3.45%, with a net profit of 341 million yuan, up 7.92% [7]